PhaseBio raises $34M to test orphan disease strategy — focusing first on AstraZeneca drug
After spending the past three years repositioning itself as an orphan disease-focused biotech, PhaseBio is ready to roll with a fresh $34 million raise. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
